Agile Therapeutics Inc. Announces Completion of Acquisition by Insud Pharma, SL Page 1

Agile common shares will no longer be listed on the OTC QB

PRINCETON, N.J., Aug. 26, 2024 (GLOBE NEWSWIRE) — Agile Therapeutics, Inc. (“Agile”) (OTCQB: AGRX), a women’s healthcare company, today announced the completion of the acquisition of Agile by Insud Pharma, SL (“Insud”), a global pharmaceutical group based in Spain with a 45-year track record and a presence in more than 50 countries.

Former Agile common stockholders voted to approve the acquisition at a special meeting of shareholders on August 22, 2024. Upon completion of the acquisition, former Agile common stockholders were entitled to receive $1.52 per share in cash, net of liabilities assumed and estimated transaction expenses, for a total enterprise value of approximately $45 million.

Insud completed its acquisition of Agile through the merger of an indirect, wholly owned subsidiary of Insud with and into Agile, with Agile continuing as the surviving company and becoming an indirect subsidiary of Insud, pursuant to a definitive merger agreement dated June 25, 2024. Upon completion of the transaction, Agile will no longer be listed on any public market.

Advisors
HC Wainwright & Co. acted as exclusive financial advisor to Agile Therapeutics, Inc. and Morgan, Lewis & Bockius LLP acted as legal counsel. Loeb & Loeb LLP and RC Law LLP acted as legal counsel to Insud Pharma, SL and Exeltis USA, Inc.

About Resilient Therapeutics, Inc.
Agile Therapeutics is a women’s healthcare company dedicated to addressing the unmet health needs of women today. Our products and product candidates are designed to provide women with contraceptive options that give them the freedom to not take a daily pill, without committing to a longer-acting method. Our first product, Twirla, (levonorgestrel and ethinyl estradiol), a transdermal system, is a non-daily prescription contraceptive. Twirla is based on our proprietary transdermal patch technology, called Skinfusion, which is designed to enable drug delivery through the skin. For more information, visit the company’s website at www.agiletherapeutics.nlThe Company may from time to time disseminate material, non-public information on the Company’s website and on its LinkedIn account.